The lack of sensitive outcome measures capable of detecting disease progression is a major limitation for the development of therapies for MS, as the current gold-standard, the EDSS, has less than optimal reliability and responsiveness. Wearable accelerometers are able to detect movement and capture comprehensive information about disability in the real-world context, providing a more accurate and objective picture of the disability. We think that metrics gathered from these devices will detect disease progression earlier in the disease process than the EDSS, and will help us better link quality of life to MS disability.
Individuals with secondary progressive multiple sclerosis (SPMS) experience significant impairments to ambulation, yet there are no therapeutic interventions yet that have been shown to improve disability for them. Functional Electrical Stimulation (FES) has been shown to increase muscles mass, improve bone density and decrease spasticity, along with many more benefits — and may perhaps even modulate the inflammatory CNS environment in progress multiple sclerosis. This study aims to study the effects of FES during cycling on walking in people with SPMS.
Multiple Sclerosis (MS) is a disease that damages myelin sheaths and axons in the brain and spinal cord, leading to disability — most often walking impairments. People with MS respond differently to progressive resistance training (PRT), which aims to improve strength for rehabilitation. For this study, we are trying to see whether an array of MRI and clinical measures can help us to predict PRT responsiveness in people with MS.
Transverse myelitis is an inflammatory disorder of the spinal cord that leads to disabilities of gait. Dalfampridine, a sustained-release potassium channel blocker that has been shown to be effective in improving gait and other neurologic functions in multiple sclerosis, has the potential to improve gait and neurologic function in patients with transverse myelitis as this rare disorder shares a similar pathogenic process with multiple sclerosis. We propose a clinical trial to test the efficacy of dalfampridine in this particular cohort of patients.
X-linked adrenoleukodystrophy (X-ALD), a progressive neurodegenerative disease, commonly presents in adult form as adrenomyeloneuropathy (AMN), a slowly progressing spastic paraparesis with sensory and autonomic dysfunction. It is unknown in the female carriers of this disease how pathological abnormalities in the spinal cord and brain, specifically in the corticospinal tract and dorsal columns, relate to the extent of disability in the women. In this study, we examined how closely MRI measures of disease pathology in women with AMN relate to their sensory and motor deficits, and, furthermore, how these measures relate to their responsiveness to PRT.